Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report, precarious financial situation, and clinical progress with lead candidate Bexmarilimab. With upcoming BEXMAB read-outs and a planned larger share issue ahead, we abstain from making any changes in our valuation for now.